Skip to main content
. Author manuscript; available in PMC: 2011 Feb 28.
Published in final edited form as: Ann Neurol. 2009 Jan;65(1):67–75. doi: 10.1002/ana.21536

Table 1.

Grip Strength and Severity Score in Severe Experimentally Acquired Myasthenia Gravis Rats Treated with Complement Inhibitor rEV576

Experiments S-EAMG Group
 S-EAMG + rEV576 Group
 Control Group
Grip Strength Severity Score Grip Strength Severity Score Grip Strength Severity Score
Experiment 1
 Day 0 380.20 ± 18.31 2 442.25 ± 10.66 2 522.40 ± 9.75a 0
 Day 10 — b — b 444.00 ± 9.60 1 553.06 ± 9.20a 0
Experiment 2
 Day 0 493.28 ± 21.27 2 486.33 ± 5.76 2 556.20 ± 10.00a 0
 Day 10 479.30 ± 12.42 2 507.90 ± 11.11c 1 576.33 ± 12.78a 0

Results are shown as ± SEM for each of the groups.

Experimentally acquired myasthenia gravis (EAMG) rats were scored and examined for the grip strength before treatment (day 0) and at the end of treatment with C5 complement inhibitor (day 10). Severity score always improved after treatment with rEV576. n = 4–7 rats in each group.

a

Significantly greater (p < 0.001) than the corresponding groups immunized with acetylcholine receptor.

b

All untreated EAMG rats in Experiment 1 were euthanized on days 1 or 2.

c

Significantly greater (p < 0.0125) than the corresponding group untreated with rEV576 (Experiment 2).

S-EAMG = experimentally acquired myasthenia gravis; SEM = standard error of the mean.